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biomedical applications. Nature has spent billions ofVaccine Delivery
years assembling nanoscale building blocks (such asby Carbon Nanotubes lipids, peptides, and nucleic acids) into complex and
functional structures. For example, selectivity and rec-
ognition at the molecular scale, such as antibody-anti-
gen interactions, is a critical feature of living systems.
Novel nanomaterials, such as carbon nanotubes, are However, nature has not had the opportunity to produce
under active investigation for potential use in biomedi- biomolecular interactions with the desired nanoscale
cal applications. In this issue of Chemistry & Biology, materials [7]. It has been shown that selective design
researchers describe antigen-antibody interactions and of peptides can be used to control interactions between
immune responses using peptide-carbon nanotube con- the biological and nonbiological world. Peptide se-
jugates. quences have been used to bind to metal particles [8]
and carbon nanotubes [4, 9, 10].
The interactions between carbon nanotubes and bio-The potential of novel nanomaterials, such as carbon
logical materials are mainly being investigated for bio-nanotubes, is enormous. These tubular arrangements
sensing (see [11, 12] and references therein). The basicof sp2 hybridized carbon atoms are under active investi-
concept for utilizing carbon nanotubes as transducersgation due to their phenomenal physical properties [1].
in biosensing applications is the ability to enable specificFor example, they can function as semiconductors in
interactions with the analyte through functionalizationnanoscale devices, be spun into the toughest material
of the nanotube surface and characterization of specific(man-made or natural [2]), or act as actuators with a
interactions (i.e., sensing) and reducing nonspecific in-force generation 100 times larger than that of mamma-
teractions.lian muscles.
In an important new development, the work by Bianco,Carbon nanotubes (CNT) exist in two types, single
Prato, and collaborators [13] published in this issuewall (SWNT) and multi wall (MWNT). SWNT have lengths
demonstrates the potential use of carbon nanotubes inof up to 10 m and diameter of up to 2 nm, depending
vaccine delivery. The basic concept for utilizing carbonon the production process. MWNT are thicker and
nanotubes in vaccine delivery is to link the antigen tolonger. CNT are not easily processed due to their lack
carbon nanotubes while retaining its conformation andof solubility in many solvents. However, the CNT carbon
thereby inducing antibody response with the right speci-atoms present an excellent platform for chemical func-
ficity. In addition, carbon nanotubes should not triggertionalization. Noncovalent and covalent functionaliza-
a response by the immune system, i.e., they should nottion has been utilized to overcome the problem of pro-
possess intrinsic immunogenicity.cessability (see [3–6] and references therein).
In previous work, the Bianco and Prato research group’sIn the last five years, inorganic nanomaterials such
carbon nanotubes were covalently functionalized withas nanocrystals, nanowires, and nanotubes have been
receiving an increasing amount of attention for potential a pyrrolidine ring through the 1,3-dipolar cycloaddition
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of azemethine ylides [14]. In a subsequent publication, in the (distant) future, instead of receiving a vaccine shot
amino-derivatized nanotubes were covalently linked to a by syringe, a patient may lick a lollypop coated with
peptide sequence derived from the foot-and-mouth dis- functionalized carbon nanotubes acting as vaccine de-
ease virus (FMDV), generating monoconjugated pep- livery systems.
tide-CNT [4]. Now this functionalization method has ex-
tended to enable the linkage of two FMDV peptide
Marc in het Panhuissequences to amino-derivatized carbon nanotubes (bis-
Department of Physics and NanoTech Instituteconjugated peptide-CNT) [13]. Standard characteriza-
The University of Texas at Dallastion techniques such as HPLC, NMR, and microscopy
2601 North Floyd Roadwere used to confirm the formation of the peptide-nano-
Richardson, Texas 75083tube covalent bonds.
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colleagues describe the crystal structure of scyptolinInhibition of Serine Proteases A, a cyclic peptide produced by cyanobacteria, com-
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related inhibitor bound to trypsin, the work may assist
in the design of reversible serine protease inhibitors.
The inhibition of enzymes employing a nucleophilic
serine residue by natural products has been studied Classic enzymology studies combined with pioneering
structural biology have led to the serine proteases beingfor many years. More recently, high-resolution struc-
tural analyses have begun to augment kinetic analy- among the best characterized of all enzyme families.
